论文部分内容阅读
内源性钠泵抑制物(ESPI)是具有抑制钠泵活性、利钠、升压、血管活性和某些洋地黄特性的内源性体液因素,它参与调节离子转运、肾脏排钠和小动脉的血管反应等,并可能在高血压发病学和心力衰竭的发生发展上具有重要意义。因而,获得ESPI的纯品,确定其化学结构,并寻求可靠的特异性的检测ESPI含量的手段,成为深入开展研究的关键。本研究采用包括高效液相色谱分析法在内纯化步骤,获得了人血浆ESPI的纯品,鉴定其生物学特征和化学结构。继而应用杂交瘤——单克隆抗体,制备出具有高特异性的ESPI单克隆抗体,为能提供一种新的、可靠、精确的ESPI定量检测手段创造了条件,为揭示
Endogenous Sodium Pump Inhibitors (ESPIs) are endogenous humoral factors that inhibit sodium pump activity, natriuretic, vasopressor, vasoactive, and certain digitalis properties and are involved in the regulation of ion transport, renal effusion, and arterioles Of the vascular response, and may be of great significance in the pathogenesis of hypertension and the occurrence and development of heart failure. Therefore, access to pure ESPI, to determine its chemical structure, and to find reliable and specific means to detect ESPI content, become the key to further study. In this study, purification steps including HPLC were used to obtain the pure ESPI of human plasma, and its biological characteristics and chemical structure were identified. Then the hybridoma-monoclonal antibody was used to prepare the ESPI monoclonal antibody with high specificity, which provided the conditions for providing a new, reliable and accurate quantitative detection method of ESPI.